| pubmed-article:20630764 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20630764 | lifeskim:mentions | umls-concept:C0024337 | lld:lifeskim |
| pubmed-article:20630764 | lifeskim:mentions | umls-concept:C1423062 | lld:lifeskim |
| pubmed-article:20630764 | lifeskim:mentions | umls-concept:C1420071 | lld:lifeskim |
| pubmed-article:20630764 | lifeskim:mentions | umls-concept:C0332256 | lld:lifeskim |
| pubmed-article:20630764 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:20630764 | lifeskim:mentions | umls-concept:C0205349 | lld:lifeskim |
| pubmed-article:20630764 | lifeskim:mentions | umls-concept:C0439098 | lld:lifeskim |
| pubmed-article:20630764 | pubmed:issue | 15 | lld:pubmed |
| pubmed-article:20630764 | pubmed:dateCreated | 2010-7-23 | lld:pubmed |
| pubmed-article:20630764 | pubmed:abstractText | Sirtuins catalyze the NAD(+) dependent deacetylation of N(epsilon)-acetyl lysine residues to nicotinamide, O'-acetyl-ADP-ribose (OAADPR) and N(epsilon)-deacetylated lysine. Here, an easy-to-synthesize Ac-Ala-Lys-Ala sequence has been used as a probe for the screening of novel N(epsilon)-modified lysine containing inhibitors against SIRT1 and SIRT2. N(epsilon)-Selenoacetyl and N(epsilon)-isothiovaleryl were the most potent moieties found in this study, comparable to the widely studied N(epsilon)-thioacetyl group. The N(epsilon)-3,3-dimethylacryl and N(epsilon)-isovaleryl moieties gave significant inhibition in comparison to the N(epsilon)-acetyl group present in the substrates. In addition, the studied N(epsilon)-alkanoyl, N(epsilon)-alpha,beta-unsaturated carbonyl and N(epsilon)-aroyl moieties showed that the acetyl binding pocket can accept rather large groups, but is sensitive to even small changes in electronic and steric properties of the N(epsilon)-modification. These results are applicable for further screening of N(epsilon)-acetyl analogues. | lld:pubmed |
| pubmed-article:20630764 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20630764 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20630764 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20630764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20630764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20630764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20630764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20630764 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20630764 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20630764 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:20630764 | pubmed:issn | 1464-3391 | lld:pubmed |
| pubmed-article:20630764 | pubmed:author | pubmed-author:SalminenAnter... | lld:pubmed |
| pubmed-article:20630764 | pubmed:author | pubmed-author:LeppänenJukka... | lld:pubmed |
| pubmed-article:20630764 | pubmed:author | pubmed-author:PosoAnttiA | lld:pubmed |
| pubmed-article:20630764 | pubmed:author | pubmed-author:SuuronenTiina... | lld:pubmed |
| pubmed-article:20630764 | pubmed:author | pubmed-author:Lahtela-Kakko... | lld:pubmed |
| pubmed-article:20630764 | pubmed:author | pubmed-author:HuhtiniemiTer... | lld:pubmed |
| pubmed-article:20630764 | pubmed:author | pubmed-author:JarhoElinaE | lld:pubmed |
| pubmed-article:20630764 | pubmed:author | pubmed-author:BruijnTanjaT | lld:pubmed |
| pubmed-article:20630764 | pubmed:author | pubmed-author:JääskeläinenS... | lld:pubmed |
| pubmed-article:20630764 | pubmed:copyrightInfo | Copyright (c) 2010. Published by Elsevier Ltd. | lld:pubmed |
| pubmed-article:20630764 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20630764 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:20630764 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:20630764 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20630764 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20630764 | pubmed:pagination | 5616-25 | lld:pubmed |
| pubmed-article:20630764 | pubmed:meshHeading | pubmed-meshheading:20630764... | lld:pubmed |
| pubmed-article:20630764 | pubmed:meshHeading | pubmed-meshheading:20630764... | lld:pubmed |
| pubmed-article:20630764 | pubmed:meshHeading | pubmed-meshheading:20630764... | lld:pubmed |
| pubmed-article:20630764 | pubmed:meshHeading | pubmed-meshheading:20630764... | lld:pubmed |
| pubmed-article:20630764 | pubmed:meshHeading | pubmed-meshheading:20630764... | lld:pubmed |
| pubmed-article:20630764 | pubmed:meshHeading | pubmed-meshheading:20630764... | lld:pubmed |
| pubmed-article:20630764 | pubmed:meshHeading | pubmed-meshheading:20630764... | lld:pubmed |
| pubmed-article:20630764 | pubmed:meshHeading | pubmed-meshheading:20630764... | lld:pubmed |
| pubmed-article:20630764 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20630764 | pubmed:articleTitle | N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2. | lld:pubmed |
| pubmed-article:20630764 | pubmed:affiliation | School of Pharmacy, University of Eastern Finland, Kuopio Campus, PO Box 1627, 70211 Kuopio, Finland. Tero.Huhtiniemi@uef.fi | lld:pubmed |
| pubmed-article:20630764 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20630764 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:20630764 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20630764 | lld:pubmed |
